SCHEMBL22772829

SCHEMBL22772829

O=C(O)n1ncc2ncc(Cl)nc21

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.34
NAPRT Q6XQN6 1/20 0.31
SIRT6 Q8N6T7 1/20 0.31
GRIN2B Q13224 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22772812 0.77 ELANE (0.38) ALDH1A1
SCHEMBL23055345 0.76 KMO (0.46) GRIN2B
SCHEMBL29892154 0.74 ELANE (0.38) NAPRT
SCHEMBL23063898 0.74 ELANE (0.38) NAPRT
SCHEMBL25205678 0.73 KMO (0.51) GRIN2B
SCHEMBL25227445 0.73 KMO (0.51) GRIN2B
SCHEMBL25227443 0.73 KMO (0.51) GRIN2B
SCHEMBL27171964 0.71 ELANE (0.40) ALDH1A1NAPRTSIRT6
SCHEMBL30329260 0.71 GRIN2B (0.45) ALDH1A1GRIN2B
SCHEMBL22835624 0.71 ALDH1A1 (0.42) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11993587-B2 Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2024-05-28 US disclosed
EP-3983413-A1 SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2022-04-20 EP disclosed
US-11214563-B2 Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2022-01-04 US disclosed
WO-2020249802-A1 SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-12-17 WO disclosed
US-20200392113-A1 SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11214563-B2 Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators GRIN2B, GRIN2A, GRIN2C ALDH1A1 2607/4885NAPRT 1177/4885SIRT6 3752/4885
US-20200392113-A1 SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN2C ALDH1A1 2607/4885NAPRT 1177/4885SIRT6 3752/4885
US-11993587-B2 Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators GRIN2B, GRIN2A, GRIN2C ALDH1A1 2607/4885NAPRT 1177/4885SIRT6 3752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.